NO326349B1 - CCR5-antagonister for behandling av AIDS, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medisin. - Google Patents

CCR5-antagonister for behandling av AIDS, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medisin. Download PDF

Info

Publication number
NO326349B1
NO326349B1 NO20034311A NO20034311A NO326349B1 NO 326349 B1 NO326349 B1 NO 326349B1 NO 20034311 A NO20034311 A NO 20034311A NO 20034311 A NO20034311 A NO 20034311A NO 326349 B1 NO326349 B1 NO 326349B1
Authority
NO
Norway
Prior art keywords
alkyl
aryl
mmol
heteroaryl
solution
Prior art date
Application number
NO20034311A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034311L (no
NO20034311D0 (no
Inventor
Michael W Miller
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20034311D0 publication Critical patent/NO20034311D0/no
Publication of NO20034311L publication Critical patent/NO20034311L/no
Publication of NO326349B1 publication Critical patent/NO326349B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20034311A 2001-03-29 2003-09-26 CCR5-antagonister for behandling av AIDS, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medisin. NO326349B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
PCT/US2002/009491 WO2002079194A1 (en) 2001-03-29 2002-03-27 Ccr5 antagonists useful for treating aids

Publications (3)

Publication Number Publication Date
NO20034311D0 NO20034311D0 (no) 2003-09-26
NO20034311L NO20034311L (no) 2003-11-26
NO326349B1 true NO326349B1 (no) 2008-11-17

Family

ID=23070981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034311A NO326349B1 (no) 2001-03-29 2003-09-26 CCR5-antagonister for behandling av AIDS, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medisin.

Country Status (30)

Country Link
US (5) US6720325B2 (ja)
EP (2) EP1373256B1 (ja)
JP (2) JP4248251B2 (ja)
KR (1) KR100613528B1 (ja)
CN (1) CN100519554C (ja)
AR (1) AR033452A1 (ja)
AT (2) ATE466009T1 (ja)
AU (1) AU2002255947B8 (ja)
BR (1) BR0208398A (ja)
CA (1) CA2442227C (ja)
CZ (1) CZ20032636A3 (ja)
DE (2) DE60236218D1 (ja)
DK (1) DK1373256T3 (ja)
ES (2) ES2242856T3 (ja)
HK (2) HK1057363A1 (ja)
HU (1) HUP0400349A3 (ja)
IL (1) IL157551A0 (ja)
MX (1) MXPA03008853A (ja)
MY (1) MY128609A (ja)
NO (1) NO326349B1 (ja)
NZ (1) NZ527768A (ja)
PE (1) PE20020996A1 (ja)
PL (1) PL364560A1 (ja)
PT (1) PT1373256E (ja)
RU (1) RU2316553C2 (ja)
SI (1) SI1373256T1 (ja)
SK (1) SK287521B6 (ja)
TW (1) TWI237638B (ja)
WO (1) WO2002079194A1 (ja)
ZA (1) ZA200307474B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60236218D1 (de) * 2001-03-29 2010-06-10 Schering Corp CCR5 Antagonisten verwendbar für die Behandlung von Aids
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
ES2312856T3 (es) 2002-12-13 2009-03-01 Smithkline Beecham Corporation Compuestos heterociclicos como antagonistas de ccr5.
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US7652142B2 (en) * 2003-11-03 2010-01-26 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
JP2007520556A (ja) * 2004-02-05 2007-07-26 シェーリング コーポレイション Ccr3アンタゴニストとして有用なピペリジン誘導体
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
GEP20094680B (en) * 2004-04-13 2009-05-10 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
US8143404B2 (en) * 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2594114A1 (en) * 2005-01-06 2006-07-13 Schering Corporation Synthesis of ccr5 receptor antagonists
CA2594109A1 (en) * 2005-01-06 2006-07-13 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
PE20061012A1 (es) * 2005-02-23 2006-10-03 Schering Corp Derivados piperidinil piperazina como inhibidores de receptores quiomicina
US7705019B2 (en) 2005-02-23 2010-04-27 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CA2673233A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
US20110059154A1 (en) * 2008-02-29 2011-03-10 Strizki Julie M Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP1103275B1 (en) 1995-06-07 2003-09-10 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein in absorbent article
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
CZ20013940A3 (cs) 1999-05-04 2002-04-17 Schering Corporation Piperazinové deriváty uľitečné jako CCR5 antagonisté
RU2266281C2 (ru) 1999-05-04 2005-12-20 Шеринг Корпорейшн Производные пиперидина, фармацевтическая композиция на их основе и способ лечения инфекции вирусом hiv
DE60236218D1 (de) * 2001-03-29 2010-06-10 Schering Corp CCR5 Antagonisten verwendbar für die Behandlung von Aids

Also Published As

Publication number Publication date
US7060701B2 (en) 2006-06-13
US20050059666A1 (en) 2005-03-17
CZ20032636A3 (cs) 2003-12-17
US6720325B2 (en) 2004-04-13
IL157551A0 (en) 2004-03-28
HK1083505A1 (en) 2006-07-07
ES2242856T3 (es) 2005-11-16
JP4248251B2 (ja) 2009-04-02
WO2002079194A1 (en) 2002-10-10
AR033452A1 (es) 2003-12-17
US6900211B2 (en) 2005-05-31
ZA200307474B (en) 2004-12-24
US20050143390A1 (en) 2005-06-30
SI1373256T1 (sl) 2005-12-31
SK11962003A3 (sk) 2004-03-02
PE20020996A1 (es) 2002-11-01
EP1591444B1 (en) 2010-04-28
PL364560A1 (en) 2004-12-13
CA2442227A1 (en) 2002-10-10
BR0208398A (pt) 2004-06-15
MXPA03008853A (es) 2003-12-04
NZ527768A (en) 2005-03-24
DE60204951D1 (de) 2005-08-11
SK287521B6 (sk) 2010-12-07
NO20034311L (no) 2003-11-26
ES2342942T3 (es) 2010-07-19
CA2442227C (en) 2008-10-28
HK1057363A1 (en) 2004-04-02
ATE466009T1 (de) 2010-05-15
KR100613528B1 (ko) 2006-08-16
JP2008074862A (ja) 2008-04-03
EP1373256A1 (en) 2004-01-02
US7008946B2 (en) 2006-03-07
RU2003131879A (ru) 2005-05-10
PT1373256E (pt) 2005-11-30
DE60204951T2 (de) 2006-05-11
US20060063771A1 (en) 2006-03-23
HUP0400349A3 (en) 2010-03-29
JP2004525157A (ja) 2004-08-19
EP1373256B1 (en) 2005-07-06
ATE299139T1 (de) 2005-07-15
DE60236218D1 (de) 2010-06-10
US7098213B2 (en) 2006-08-29
RU2316553C2 (ru) 2008-02-10
CN100519554C (zh) 2009-07-29
KR20030083014A (ko) 2003-10-23
EP1591444A1 (en) 2005-11-02
NO20034311D0 (no) 2003-09-26
AU2002255947B2 (en) 2005-10-27
US20040157854A1 (en) 2004-08-12
CN1547580A (zh) 2004-11-17
HUP0400349A2 (hu) 2004-12-28
TWI237638B (en) 2005-08-11
AU2002255947B8 (en) 2005-11-17
MY128609A (en) 2007-02-28
US20030008877A1 (en) 2003-01-09
DK1373256T3 (da) 2005-10-10

Similar Documents

Publication Publication Date Title
NO326349B1 (no) CCR5-antagonister for behandling av AIDS, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medisin.
TW454007B (en) Novel isoxazoline and isozazole fibrinogen receptor antagonists
UA125032C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ RЕТ-КІНАЗИ
US8153658B2 (en) Piperidine derivative or salt thereof
UA123010C2 (uk) Модулятори сот та способи їх застосування
TW201130816A (en) New CCR2 receptor antagonists and uses thereof
TW200815426A (en) New pyridine analogues II 333
JP2010018635A (ja) カンナビノイドレセプターリガンド
TW200815431A (en) Azabenzimidazolyl compounds
WO2004002964A1 (ja) ジアミノピリミジンカルボキサミド誘導体
CZ200036A3 (cs) Triazolové sloučeniny a jejich použití
CZ20013940A3 (cs) Piperazinové deriváty uľitečné jako CCR5 antagonisté
JP2008531679A (ja) オキシトシンアンタゴニストとしての1,2,4−トリアゾール誘導体とその使用
WO2009022730A1 (ja) P2x4受容体拮抗剤
TW492960B (en) Azetidine derivatitives, relevant processes of manufacture and the uses thereof as tachykinin inhibitors
HU229709B1 (en) Piperazinyilpiperidine derivatives as chemokine receptor antagonists
TW200808707A (en) Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
CA2927182A1 (en) Quinolinyl modulators of ror.gamma.t
TW201326143A (zh) G蛋白偶合mas受體之調節劑及與其相關病症之治療
US20100324017A1 (en) Acylguanidine derivative
NO159272B (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive dihydropyridiner.
TW200800194A (en) Kinase inhibitors
CN110248935A (zh) 用于治疗疼痛和疼痛相关病症的含氮二环衍生物
JP4717815B2 (ja) イソキノリノンカリウムチャネル阻害剤
TWI296926B (en) Interleukin-4 gene expression inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees